SRL,Inc.is commissioned by hospitals and clinics across Japan to perform more than 200,000 tests per day. This page provides a general introduction to SRL,Inc.’s Non-Clinical testing characteristics, representative disease models, and case studies to assist sponsor organizations in selecting a Non-Clinical CRO.
SRL,Inc. maintains an integrated framework that provides consistent support from study preparation through execution, data management, and regulatory submission support. By contracting multiple processes together—such as testing, data management, and data/assay monitoring—SRL,Inc. helps reduce sponsor burden and enables efficient, high-quality study operations. SRL’s extensive portfolio of animal disease models allows selection of models appropriate to a range of indications, supporting both efficacy and toxicology work and contributing to more efficient drug-discovery cycles.
Using advanced analytical technologies, SRL,Inc. conducts a broad menu of Non-Clinical testing, including pharmacokinetic and toxicology studies. SRL,Inc. performs testing across diverse fields such as biochemistry, endocrinology, oncology, virology, immunology, genetics, and pathology, and implements studies using advanced techniques including real-time PCR, flow cytometry, and pharmacogenomics.
SRL,Inc.’s quality management has been developed through extensive experience in contract clinical testing. The organization operates under a rigorous quality control framework and employs quality-assurance systems aligned with international standards, such as ISO 15189 held by the clinical diagnostics arm, and actively incorporates external evaluations. SRL provides consistent, high-accuracy services from sample receipt and handling (with appropriate chain-of-custody) through data reporting, enabling reliable study operations.
NIHON RINSHO provides high-quality services spanning multiple aspects of healthcare and daily life, centered on contract clinical laboratory testing to address a broad range of testing needs from medical institutions, as well as pharmaceutical analysis and supply sales. Services are delivered through a 24-hour comprehensive laboratory equipped with analytical instruments and supported by a proprietary information system that manages the process end-to-end—from order intake through reporting.
Hoku-shin Clinical provides comprehensive contracted clinical laboratory services and consultation related to clinical testing and laboratory equipment, primarily in Nagano Prefecture. As a partner to regional medical institutions, the company supplies reliable clinical laboratory data through outsourced testing services.
No case studies are currently listed on the official website.
SRL,Inc. provides contract clinical laboratory testing services for medical institutions, offering a broad menu that includes advanced genetic testing/analysis, pathology, and cancer gene panel testing. SRL also provides support for hospitals and clinics and clinical research. In addition, the company offers services related to SARS-CoV-2 (COVID-19) testing and genomic medicine.
| Address | Akasaka Intercity AIR, 1-8-1 Akasaka, Minato-ku, Tokyo, Japan |
|---|---|
| Tel | 03-6279-0900 |
| Website | https://www.srl-group.co.jp/ |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.